Other languages MannKind Corporation

Equities

MNKD

US56400P7069

Real-time Estimate Cboe BZX Other stock markets 03:51:37 2024-07-09 pm EDT			5-day change	1st Jan Change
5.365 ^USD	-0.46%		+6.66%	+47.39%

Jun. 22	MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study	CI
May. 29	MannKind Agrees to Cross License Deal With Pulmatrix	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study	Jun. 22
MannKind Agrees to Cross License Deal With Pulmatrix	May. 29
Pulmatrix, Inc. Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	May. 29
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment	May. 06
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease	May. 06
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	Apr. 30
MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	Apr. 29
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease	Apr. 29
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects	Mar. 26
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	Mar. 11
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	Feb. 15
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	Jan. 02
MannKind Sells 1% Royalty on Tyvaso DPI Net Sales for Up to $200 Million	Jan. 02
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals	Dec. 28
Mannkind Insider Sold Shares Worth $801,928, According to a Recent SEC Filing	Dec. 18
MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes	Nov. 06
MannKind Receives US Patent for Clofazimine Inhalation Suspension to Treat Lung Disease	23-10-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MannKind Corporation

Equities

MNKD

US56400P7069

Other languages

Filters